化合物YQ128
化合物YQ128 性质
| 沸点 | 705.8±70.0 °C(Predicted) |
|---|---|
| 密度 | 1.287±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 二甲基亚砜：250 mg/ml（458.62 mM） |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 9.32±0.50(Predicted) |
| 颜色 | 白色至米白色 |
| InChIKey | SFPYRFRNYALLHS-UHFFFAOYSA-N |
| SMILES | C1SC=CC=1CC(N(CC1=CC(Cl)=CC=C1OCCC)CCC1=CC=C(S(NCC#C)(=O)=O)C=C1)=O |
化合物YQ128 用途与合成方法
|
NLRP3 0.30 μM (IC 50 ) |
IL-1β
|
YQ128 (0.3-100 µM; 30 mins) dose dependently suppressed the release of IL-1β from peritoneal macrophages upon LPS/ATP challenge with an IC
50
of 1.59 µM.
YQ128 (20 µM; 2 hours) shows no significant toxic effects on hCMEC/D3 cells.
Cell Viability Assay
| Cell Line: | Mouse peritoneal macrophages |
| Concentration: | 0.3, 1.0, 3.0, 10, 30, 100 µM |
| Incubation Time: | 30 mins |
| Result: | Suppressed the release of IL-1β from peritoneal macrophages upon LPS/ATP challenge with an IC 50 of 1.59 µM. |
YQ128 (iv; 20 mg/kg) has an intermediate terminal plasma half-life (t
1/2
) of 6.6 hours after iv administration.
YQ128 (oral; 20 mg/kg) shows delayed gastrointestinal absorption with a t
max
and c
max
of 12 h and 73 ng/mL, respectively. Oral bioavailability (F
oral
) is estimated as 10%.
YQ128 exhibits extensive extravascular distribution with a large steady-state volume of distribution (Vd
ss
) of 8.5 L/kg and rapid total clearance (CL
tot
) of 41 mL/min/kg.
YQ128 (10 mg/kg) has been shown to trigger IL-1β production in a NLRP3- dependent manner in C57BL/6 mice.
| Animal Model: | Sprague-Dawley rats (200-250 g) |
| Dosage: | 20 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Iv |
| Result: | Had an intermediate terminal plasma half-life (t 1/2 ) of 6.6 hours after iv administration. |
化合物YQ128 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-130252 | 化合物YQ128 | 2454246-18-3 | 1 mg | 556 |
| 2026-09-15 | HY-130252 | 化合物YQ128 | 2454246-18-3 | 5 mg | 1300 |
